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Abstract
Background: RNA virus populations are heterogeneous ensembles of closely related genomes termed quasispecies. This
highly complex distribution of variants confers important properties to RNA viruses and influences their pathogenic
behavior. It has been hypothesized that increased mutagenesis of viral populations, by treatment with mutagenic agents,
can induce alterations in the pathogenic potential of a virus population. In this work we investigate whether mutagenized
foot-and-mouth disease virus (FMDV) populations display changes in their virulence in mice.
Methodology and Principal Findings: FMDV C-S8c1 was passaged in BHK cells in the presence of the mutagenic agent
ribavirin. Decline in viral titer and viral RNA progeny was observed in the first passage, fluctuating around a constant value
thereafter. Hence, the specific infectivity remained stable during the passages. The viral population harvested from passage
9 (P9 R) showed decreased virulence in mice, with a lethal dose 50 (LD50) .10
4 PFU, as compared with LD50 of 50 PFU of the
parental population FMDV C-S8c1. This decrease in virulence was associated to a 20-fold increase in the mutation frequency
of the P9 R population with respect to C-S8c1. Interestingly, individual biological clones isolated from the attenuated
population P9 R were as virulent as the parental virus C-S8c1. Furthermore, a mixed population of C-S8c1 and P9 R was
inoculated into mice and showed decreased virulence as compared to C-S8c1, suggesting that population P9 R is able to
suppress the virulent phenotype of C-S8c1.
Conclusion: Ribavirin-mediated mutagenesis of an FMDV population resulted in attenuation in vivo, albeit a large
proportion of its biological clones displayed a highly virulent phenotype. These results, together with the suppression of C-
S8c1 by mutagenized P9 R population, document a suppressive effect of mutagenized viral quasispecies in vivo, and
suggest novel approaches to the treatment and prevention of viral diseases.
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Introduction
RNA viruses replicate as complex mutant distributions termed
viral quasispecies [reviews in [1–4]. This means that replicative
ensembles of non-identical genomes are generated within infected
cells, and that different variants can coinfect cells as replication
proceeds. Several studies have documented that internal interac-
tions among viral gene products of the same replicative ensemble
(or mutant spectrum) may result in either survival of defective
genomes by complementation or in suppression of higher fitness
virus by lower fitness mutant distributions [2,4–8]. Complemen-
tation among components of a viral quasispecies replicating under
standard mutation rate may also underlie the observation that
replicative fitness (relative capacity to produce infectious progeny)
of individual clones is, on average, lower than the fitness of the
entire (uncloned) populations from which the clones were isolated
[9,10].
Several important biological properties of RNA viruses are
heavily influenced by the complexity (number of different genomic
sequences and average number of mutations per genome) and
composition of mutant spectra. Among them, the presence of
memory in viral quasispecies, the rate of disease progression, the
response to antiviral treatments, and the pathogenic potential of
a virus, as documented with the decreased neuropathology
displayed by a high fidelity mutant of poliovirus that produces
a less complex mutant spectrum than the wild-type virus [11,12].
High fidelity mutant viruses constitute a new generation of
candidate attenuated vaccines ([13–14]; reviewed in [2,4]). In cell
culture, the interaction between two foot-and-mouth disease virus
(FMDV) subpopulations, which had evolved from a single parental
genome, modulated the cell killing capacity of the population [15].
In a study of infection of adult mice with FMDV, the virus isolated
from pancreas was highly attenuated for mice although the virus
showed indistinguishable consensus genomic nucleotide sequence
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isolated from sera of the same animals [16]. Thus, mutant spectra
of viral populations may encode virulence determinants not readily
associated with the complexity of the mutant spectrum or with
a specific, dominant genome sequence. Overall, these observations
reinforce the concept that it is an ensemble of genomes –rather
than individual genomes within the ensemble– the one that
determines virus behavior. Interestingly, this corresponds to the
tenet of quasispecies theory of the mutant spectrum being the
target of selection [17–19]. In quasispecies theory, selection of
ensembles was due to the high connectivity of genomes in
sequence space, and in the case of viruses the selection is prompted
not only by connectivity in sequence space but also by the
interactions among gene products of related viral genomes at
a functional level [4].
Interfering interactions within mutant spectra may also be one
of the mechanisms of virus extinction by elevated mutation rates in
a process that has been termed lethal mutagenesis or transition
into error catastrophe [20–25]. Defective genomes, generated by
mutation of the standard viral genomes when viral replication
occurs in the presence of a mutagenic agent, may interfere with
replication of infectious virus, thereby contributing to viral
extinction [26–29]. Unless mutagen-resistance mutations are
selected, passage of a virus in the presence of a mutagenic agent
often results in virus extinction accompanied of logarithmic
decreases of specific infectivity (measured as PFU/viral RNA
molecules), and with an invariant consensus genomic nucleotide
sequence [26–30]. Other than examining the events associated
with extinction at the level of quasispecies complexity and its
variations [31], no other biological effects of enhanced mutagen-
esis on the behavior of RNA viruses have been studied.
Mutagenized viral populations, by virtue of containing a broader
mutant repertoire, might manifest an enhanced adaptive and
pathogenic potential as observed with poliovirus quasispecies
replicating under standard (or lower than standard) mutation rates
[11,12]. Alternatively, mutagenized quasispecies may display
reduced adaptability due to the presence of defectors [28–
30,32,33]. To investigate whether mutagenized FMDV popula-
tions showed an increase or a decrease of virulence we used the
FMDV C-S8c1-adult C57BL/6 mice system, which displays
features of FMDV infection of natural hosts (cloven-hoofed
animals) [16,34]. FMDV is a positive ssRNA virus, which belongs
to the Picornaviridae family. It encodes for low fidelity polymerases,
known as 3D, that has been shown to incorporate mutagenic
nucleotides, such as ribavirin triphosphate [35]. FMDV C-S8c1
was passaged in BHK-21 cells in the presence of ribavirin to
increase the complexity of the mutant spectrum of the viral
population and, equivalent amounts of infectious virus from
different passages were tested for their virulence in mice. The
results show that while the specific infectivity did not decrease
significantly in the course of passages in the presence of ribavirin,
lethality for mice decreased with passage number. Interestingly,
five biological FMDV clones isolated from the passaged popula-
tion with decreased virulence, showed high lethality for mice. This
implies that the attenuated phenotype was conferred by the viral
population as a whole, and that the mutant spectrum included
biological clones, which individually depicted high virulence.
Results
Passage of FMDV C-S8c1 in the presence of ribavirin
results in sustained specific infectivity
Biological clone FMDV C-S8c1 [36] was passaged in BHK-21
cells in the presence of 5 mM ribavirin (Figure 1). Infectivity and
viral RNA levels were determined at each passage (Figure 2A and
B). After a decline in titer and viral RNA progeny in the first
passage in the presence of ribavirin, viral titers and RNA levels
remained approximately constant until at least passage 9. As
a consequence, no clear trend towards either an increase or
decrease in specific infectivity was manifested, despite some
variations during the nine serial passages (Figure 2C). Unaffected
high titers and RNA levels were observed in untreated FMDV C-
S8c1 along passages resulting likewise in constant specific in-
fectivity values (Figure 2).
FMDV virulence for mice decreases with the number of
passages in the presence of ribavirin
FMDV C-S8c1 is lethal for C57BL/6 mice, with a lethal dose
50 (LD50) value of 50 PFU [34]. To investigate whether passage of
FMDV C-S8c1 in the presence of ribavirin decreased the lethality
of the virus for mice, equal PFU (10
3) of FMDV C-S8c1 or P1 R,
P4 R, P7 R and P9 R were inoculated into mice and the
percentage of animals that survived was determined (Figure 3).
Controls included animals inoculated with culture medium
(DMEM) with or without ribavirin, C-S8c1 in the presence of
ribavirin, and C-S8c1 passaged 9 times in the absence of ribavirin
(P9 untreated). Virulence of P9 R and P7 R, calculated as the
percentage of survival of inoculated mice, was significantly lower
than that of either the parental virus FMDV C-S8c1, or the
mixture of FMDV C-S8c1 and 5 mM ribavirin (Logrank Test;
p=0.001). Thus, despite the virus maintaining a relatively
constant specific infectivity (Figure 2C), its pathogenicity decreased
with the number of passages in the presence of ribavirin. The
different controls used indicated that passage in the presence of
ribavirin is a necessity for the decrease of mouse lethality. The
survival of mice inoculated with 10
1 to 10
4 PFU of FMDV P9 R
indicated that the LD50 for this virus population was higher than
10
4 PFU, a value which represents at least 200-fold lower lethality
than that of C-S8c1 (Figure 3C) [34].
Virulence is a collective property of population FMDV P9
R
To investigate whether the low virulence of population P9 R
reflected the virulence of the majority of viable (plaque-forming
positive) clones that compose the population, virus from five
biological clones derived from population P9 R was obtained by
dilution and plating on BHK-21 cell monolayers. Each of the
clones analyzed showed higher virulence in mice than the parental
viral population P9 R from which they were isolated (Figure 4). In
particular, biological clones c1, c2, c3, and c4 displayed
significantly higher virulence than P9 R (Logrank Test,
p=0.001). Thus, population P9 R included highly virulent virus
whose capacity to kill mice was not manifested in the context of the
entire viral population. The reduced virulence of P9 R is
a collective property of the mutagenized quasispecies.
A single mutation distinguishes FMDV population P9 R
from C-S8c1
To identify whether some dominant mutations distinguished
population FMDV P9 R from its parental biological clone C-S8c1,
the full genome sequence of P9 R was determined, and compared
with that of C-S8c1 [37]. In the consensus sequence of P9 R, the
only mutation that was present as a mixture with the wild-type
nucleotide was U5087C, which gives rise to amino acid sub-
stitution I248T in viral protein 2C. This mutation was not
detected after the first passage in the presence of ribavirin (P1 R)
and its proportion varied in later passages in the presence of
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population P9 R, it was present in each of the five biological clones
that displayed high virulence for mice (compare Figures 4 and 5).
In addition, we have previously shown that C-S8c1 infectious
clone harboring the mutation I248T in 2C displays similar
virulence to that of the wild-type sequence clone in infections in
mice [16].
The ribavirin-resistance mutations previously described in
FMDV and poliovirus map in the viral polymerase (3D) (P44S,
G62S, P169S and M296I; residues are numbered according the
Figure 1. Scheme of passages of FMDV C-S8c1 in BHK-21 cells in the presence of ribavirin. FMDV C-S8c1 was subjected to nine passages
in BHK-21 cells in the presence of 5 mM of ribavirin. The viral population isolated from each passage is identified as a P followed by the passage
number and R. The initial viral infection was performed at a moi of 0.1 PFU/cell, and subsequent infections were carried out with 1/10 of the volume
of the previous passage (moi in the range of 0.01–0.1 PFU/cell). Five biological clones, represented as black squares, were isolated from viral
population P9 R by dilution and plating on BHK-21 cell monolayers, as indicated with a dotted line on the right.
doi:10.1371/journal.pone.0039941.g001
Figure 2. Viral titers, RNA molecules and specific infectivity of C-S8c1 along passages in BHK-21 cells. Viral titer (A), number of viral RNA
molecules/ml (B), and specific infectivity (C) values of C-S8c1 passaged in the presence of 5 mM ribavirin are compared to those obtained in the
absence of the drug. Viral titer is expressed as PFU/ml. The specific infectivity represents the ratio between viral titer and number of RNA molecules,
shown in A and B. Procedures for the infections with FMDV, and determinations of infectivity and viral RNA are detailed in Materials and Methods.
doi:10.1371/journal.pone.0039941.g002
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did not show any mutation in the 3D-coding gene, we analyzed
this region (nucleotides 6800 to 7773; amino acids 65 to 453) in 30
molecular clones from population P9 R. The results (Table 1)
revealed 37 different mutations, 10 of which were repeated in two
or more clones. There were a total of 14 amino acid substitutions,
although none corresponding to the previously described ribavirin-
resistance mutations in FMDV [38,39,41].
One of the mutations led to a termination codon within the 3D-
coding region (C7237U, CAG to UAG), suggesting that replica-
tion in the presence of ribavirin might have increased the
proportion of defective genomes in population P9 R (see
Discussion). The number of mutations scored in population P9
R represented an increase of 20-fold in the minimum mutation
frequency, 31-fold in the maximum mutation frequency, and 10-
fold in Shannon entropy, relative to the parental C-S8c1
population (Table 2). Passaging of C-S8c1 in BHK-21 cells in
the absence of ribavirin has been previously shown to have little
effect on the mutation frequency of the viral population [33,43]. It
has been described that mutation frequencies in the 3D coding
region of C-S8c1 passaged four or 25 times in BHK-21 cells in the
absence of ribavirin are 2.2610
24 and 2.8610
24 respectively, 6.4
and 5.0 times lower than the mutation frequency of P9 R
(1.4610
23, Table 2). The distribution of mutation types in the
mutant spectrum of P9 R revealed a great dominance of CRU
and GRA mutations (78.3% of the total) (Table 3), as expected
from the mutagenic action of ribavirin on FMDV [38,41,44].
Thus, replication of FMDV C-S8c1 in the presence of high
ribavirin concentrations produced an extremely complex viral
population that was highly attenuated for mice, despite including
virulent biological clones.
FMDV C-S8c1 is suppressed by the mutagenized
quasispecies P9 R
In order to determine if the viral population P9 R, highly
attenuated in mice, can suppress the parental virus C-S8c1 in vivo,
Figure 3. Virulence in mice of FMDV C-S8c1 passaged in BHK-21 cells in the presence of ribavirin. In A) and B) groups of six mice were
inoculated into the footpad with 10
3 PFU of each viral population or culture media, as indicated in the boxes. Percentage of survival of the inoculated
mice during a follow-up period of 168 hours is represented. Samples are shown in two separate graphics for a better visualization. A) Percentage of
mice that survived following inoculation with viral populations recovered from passages 1, 4, 7 and 9 of FMDV C-S8c1 in BHK-21 cells in the presence
of 5 mM ribavirin (virus nomenclature is according to Figure 1). B) Percentage of mice that survived following inoculation with several control
samples. Positive controls correspond to mice infected with FMDV C-S8c1, a mixture of FMDV C-S8c1 and 5 mM of ribavirin, or the viral population
resulting from nine passages in BHK-21 cells in the absence of ribavirin (P9 untreated). Negative controls include mice inoculated with DMEM (the
medium in which viruses were diluted), DMEM with 5 mM ribavirin, or the supernatant of a non-infected BHK-21 cell culture maintained during
24 hours in DMEM 5 mM ribavirin (Mock passage 1). C) LD50 of viral population P9 R. Groups of six mice were inoculated into the footpad with the
number of PFU of population P9 R indicated in the box. The percentage of mice that survived was calculated over a follow-up period of 168 hours.
Procedures are detailed in Materials and Methods.
doi:10.1371/journal.pone.0039941.g003
Figure 4. Lethality of biological clones isolated from popula-
tion P9 R. Groups of six mice were inoculated into the footpad with
10
3 PFU of P9 R or of each of the 5 biological clones (c1 to c5) obtained
as plaque-isolates from population P9 R. The nomenclature of the virus
corresponds to that described in Figure 1. Percentage of survival of the
inoculated mice during a follow-up period of 168 hours is indicated.
Procedures are detailed in Materials and Methods.
doi:10.1371/journal.pone.0039941.g004
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population of C-S8c1 and P9 R at a ratio 1:20 (50 PFU of C-
S8c1+10
3 PFUs of P9 R), or C-S8c1 alone (50 PFU). The
percentage of survival during a follow-up period of 168 hours was
quantified (Figure 6). C-S8c1 alone displayed higher virulence
than C-S8c1 mixed with the complex population P9 R, although it
did not reach significance. This result suggests that the complex P9
R population is able to partially suppress the highly virulent C-
S8c1 in infections in vivo.
Discussion
Quasispecies dynamics has as one of its major biological
implications that viral pathogenesis may be determined by
ensembles of genomes that populate the mutant spectrum rather
than by a specific mutant type [11–13,45]. In the present study we
have examined the behavior of a ribavirin-mutagenized FMDV
population with regard to lethality for adult mice, an animal model
previously validated as surrogate for the prohibitive large animal
infections with FMDV [34]. Previous studies on FMDV muta-
genesis in cell culture indicated that heavily mutagenized viral
populations interfered with the replication of the standard FMDV
genomes [26,33]. Interference was further documented with
specific FMDV mutants that included defined amino acid
substitutions either in the capsid or in the polymerase, and that
had as a common trait being competent in RNA replication [29].
Ribavirin has been shown to be mutagenic for a wide range of
RNA viruses including FMDV, which typically results in a decrease
of virus infectivity and occasionally the extinction of the virus
population [7,44,46,47] Interference by mutants generated by
ribavirin played a role in viral extinction and was one of several
determinants rendering sequential administration of an inhibitor
followed by a mutagen advantageous relative to the corresponding
combination treatment [28]. The results with FMDV are in
agreement with those obtained with the arenavirus lymphocytic
choriomeningitis virus (LCMV) with a similar experimental
design, and support the participation of defective genomes in
virus extinction [27,47,48].
The present study addresses whether an FMDV population that
was mutagenized by passaging the virus in the presence of
ribavirin in BHK-21 cells could manifest some alteration of
virulence in vivo, as determined with a mouse model for FMDV
[16,34]. Population P9 R displayed a significant increase in
mutant spectrum complexity (Table 2), but the specific infectivity
was not significantly altered relative to the initial biological clone
(Figure 2), suggesting that the population did not initiate
a transition towards extinction. The reason for the sustained
infectivity of biological clone C-S8c1 in the presence of 5 mM
Figure 5. Complete genomic consensus nucleotide sequence of population P9 R and partial sequence of biological clones. A
schematic representation of FMDV genome is displayed at the top of the figure [based on [64–66]. The entire genomic sequence of FMDV population
P9 R and partial sequences, comprising residues 4945 to 5677 of FMDV populations P7 R, P4 R and P1 R, and P9 R-derived clones c1, c2, c3, c4 and c5
were determined. Virus nomenclature is that of Figure 1. Nucleotide substitutions relative to the parental virus C-S8c1 are represented inside the
boxes below the corresponding genomic region in which they are found. For non-synonymous mutations the corresponding amino acid replacement
is given in parenthesis. An equivalent mixture of C (parental) and U (mutant) nucleotides in the genomic position 5087 is represented by C/U; a higher
proportion of C than U (about 75% C) is indicated as C/u. Substitution C5087U leads to amino acid replacement I248T in viral protein 2C. Residue
numbering is accordingly to [61].
doi:10.1371/journal.pone.0039941.g005
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a role. It has been previously described that this substitution in the
context of a ribavirin-resistant FMDV C-S8c1 triple mutant
expressing a polymerase with substitutions P44S, P169S and
M296I increased the fitness of the triple mutant in the presence of
5 mM ribavirin [38]. Therefore, I248T in 2C together with
constellations of mutations in 3D or other viral proteins may limit
the sensitivity of the population to ribavirin. The mutations that
Table 1. Mutations identified in the 3D coding region in the mutant spectrum of the population passaged in the presence of
ribavirin P9 R and the parental FMDV population C-S8c1.
Viral population
a Nucleotide substitution
b Amino acid replacement
c Molecular clone number
d
C-S8c1 C7407U --- C26
U7658G --- C14
P9 R U6846C --- C21
C6881U T91M C17
G6882A --- C5
G6909A --- C16
G6925A D106N C8
G6949A D114N C20
C6978U --- C9, C12, C18, C22, C25
G7027A G140R C4
C7046U A146V C6
A7061C E151A C26
U7083C --- C11, C23
C7086U --- C16, C4
G7120A E171K C2
U7131C --- C3
C7155U --- C8
U7176C --- C7, C10, C16
A7212G --- C4
C7237U Q210Stop C15
G7324A V239M C14
G7326A --- C13
C7350U --- C1
C7353U --- C27
G7452A --- C21
C7458U --- C12, C22, C25
G7465A E286K C27
G7486A E293K C11, C23
G7489A G294S C21, C4
G7584A --- C4
G7585A V326I C1
C7623U --- C27
C7641U C12, C22, C25
U7650C --- C4
C7651U --- C7, C10, C16
C7665U --- C12, C22, C25
C7697U T363I C3
A7699G I364V C2
C7755U ---- C4
aPopulation P9 R is that derived from passaging FMDV C-S8c1 nine times in the presence of 5 mM ribavirin, as detailed in the legend for Figure 1 and in Materials and
Methods. C-S8c1 is the parental population used to initiate the passages.
bThe mutations observed in the mutant spectrum of P9 R and C-S8c1 are indicated. The total number of nucleotides sequenced, mutation frequency and Shannon
entropy are given in Table 2.
cAmino acid substitutions deduced from the mutations listed in the second column. A dash line means a synonymous mutation.
dThe molecular clones have been numbered to identify linked and repeated mutations.
doi:10.1371/journal.pone.0039941.t001
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to be determined but they are not those mutations in 3D
previously identified as conferring FMDV resistance to ribavirin
[38,39,41]. In particular, the mutant spectrum of P9 R included
a ratio of (CRU)+(GRA)/(URC)+(ARG) transitions of 4.14,
a value which corresponds to the ratio previously observed upon
passage of pMT28 in the presence of ribavirin [38]. A ratio of 4.14
excludes the presence of dominant amino acid substitutions that
could modulate the types of transition types induced by ribavirin
therefore favoring viral survival, as previously documented with
amino acid P44S in 3D of FMDV [49]. The different behavior of
FMDV C-S8c1 and the progeny of molecular clone pMT28
regarding replication under high ribavirin concentrations is
presently under investigation.
Despite a stasis in specific infectivity values (based on infectivity
determined with a plaque assay using BHK-21 cells), the
progressively complex FMDV population showed a gradual
decrease of virulence in mice, manifested already after a single
virus passage in the presence of ribavirin (Figure 3). The decrease
in virulence cannot be attributed to the presence of some ribavirin
contaminating the viral population because the inclusion of 5 mM
ribavirin in a C-S8c1 preparation resulted in no survival of mice at
120 h to 168 h p.i. P9 R showed very limited virulence, with more
than 80% survival at 72 h to 168 h p.i. (Figure 3). Interestingly,
however, most of the biological clones isolated from P9 R
displayed as high virulence in mice as the lethal clone C-S8c1
(Figure 4). This suggests that the virulence of a large proportion of
plaque-forming viruses was suppressed by the mutagenized
populations that surrounded them. Furthermore, P9 R was shown
to partially suppress the parental virus C-S8c1 (Figure 6).
Suppressive effects of mutant spectra on high fitness variants have
been previously documented both in cell culture and in vivo [6,50–
53]. In the case of ribavirin-mutagenized FMDV population P9 R
it could be argued that all the components of its mutant spectrum
were equally attenuated and that the virulent clones isolated were
generated by mutations that arose during plaque formation. This
unlikely possibility would imply that virulence-restoring mutations
are produced in cell culture and not in the animal, again arguing
in favor of suppressive effects of the complete quasispecies.
It may appear as if the results reported here are contradictory to
those obtained with poliovirus in which the attenuation for mice
was attained by a high fidelity mutant that produced a narrow
mutant spectrum [11,12], the opposite than the mutant spectrum
of FMDV whose increased complexity resulted also in attenuation.
This difference suggests that in the case of poliovirus, attenuation
was associated with a deficiency in variability and adaptability,
whereas in the case of FMDV, attenuation resulted from an excess
of mutant genomes known to mediate interfering interactions. In
both cases the results point to the need to examine the mutant
spectrum of viral populations to understand the biological
behavior of viruses [3,4].
In summary, our resuts show that increased mutagenesis of
a highly virulent RNA virus can reduce its virulence in vivo and
that interefering interactions play an important role in the
attenuation of the viral population. Thus, these findings encourage
new investigations to optimize mutagen-based antiviral strategies
for the treatment of RNA virus associated diseases.
Materials and Methods
Ethics Statement
All the experiments involving animals were approved by the
ethical review committee at the Centro de Investigacio ´n en
Table 2. Mutant spectrum complexity of P9 R and C-S8c1.
Viral population
a Genomic region
b
Number of clones
analyzed
Number of
nucleotides
c Mutation frequency Sn
f
minimum
d maximum
e
C-S8c1 3D (6800–7773) 30 29220 6.8610
25 6.8610
25 0,09
P9 R 3D (6800–7773) 27 26298 1.4610
23 2.1610
23 0,9
aThe viral populations are those described in Figure 1.
bThe numbering of FMDV genomic residues is according to reference (Escarmı ´s et al. 1999).
cNumber of nucleotides sequenced in each viral population.
dThe minimum mutation frequency is the number of different mutations divided by the total number of nucleotides sequenced for each viral population.
eThe maximum mutation frequency is the total number of mutations divided by the total number of nucleotides sequenced for each viral population
fSn, indicates normalised Shannon entropy, that is a measure of the proportion of different sequences in a distribution. It was calculated as described in Materials and
Methods.
doi:10.1371/journal.pone.0039941.t002
Table 3. Types of mutations found in the mutant spectra of P9 R and C-S8c1.
Viral population
a Transitions
b Transversions
b
URCC RUG RAA RG Total URGA RC Total
C-S8c1 0 1 (50%) 0 0 1 1(50%) 0 1
P9 R 5 (13,5%) 15 (40,5%) 14 (37,8%) 2 (5,4%) 36 0 1 (2,7%) 1
aThe viral populations are according to Figure 1.
bThe mutations are those found in the analysis of the mutant spectra of C-S8c1 and P9 R described in Table 1. The percentage of each type of mutation in relation to the
total number of mutations found in the same population is shown in brackets. Transversions CRG, GRC, URA, ARU, GRU and CRA were not observed in the
analysis.
doi:10.1371/journal.pone.0039941.t003
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European Union (Directive 86/609/EEC).
Viruses and cells
Procedures for infection of BHK-21 cell monolayers with
FMDV in liquid medium [Dulbecco’s modification of Eagle’s
medium (DMEM)] and for plaque assays in semisolid agar
medium were carried out as previously described [36,54]. FMDV
C-S8c1 is a plaque-purified derivative of natural isolate C1-Sta
Pau-Spain 70, a representative of the European subtype C1
FMDV [36]. Serial infections of FMDV C-S8c1 in BHK-21 cells
in the presence of 5 mM ribavirin were carried out as previously
described [28]. Briefly, 2610
6 BHK-21 cells were pre-incubated
for 6 to 8 hours with 5 mM ribavirin (in 1% foetal calf serum
(FCS), DMEM) to allow its penetration into cells and incorpora-
tion to cellular metabolic pathways [44]. Then, supernatants were
removed, cells inoculated with FMDV C-S8c1 for 1 h at 37uCt o
allow virus adsorption, the monolayers washed, and DMEM (1%
FCS) containing 5 mM ribavirin added to the infected cell
monolayers. The infected cultures were incubated at 37uC for
24 hours or until complete cytopathology was observed, and the
resulting supernatants were collected. The cytotoxicity of 5 mM
ribavirin on BHK-21 cells has been previously assessed, with
a reduction on cell viability of around 40% observed after
48 hours of treatment [7]. It must be noted that biological clone
FMDV C-S8c1 used in the present study displays increased
resistance (delayed extinction) than molecular clone pMT28 upon
serial passages in the presence of ribavirin [7]; pMT28 is an
infectious transcript that reproduces the consensus sequence of C-
S8c1, except for having a shorter poly C tract [37,55]. The
mechanism that underlies the different resistance to ribavirin of
biological clone C-S8c1 and molecular clone pMT28 has not been
investigated.
Biological cloning of the C-S8c1 population passaged 9 times in
the presence of ribavirin (P9 R) (Figure 1) was carried out by
isolating virus from randomly chosen, well-isolated, individual
virus plaques, avoiding biases due to plaque size, as previously
described [16,36,56,57].
Mice and infections
Seven to eight weeks-old C57BL/6 female mice were purchased
from Harlan Interfauna Ibe ´rica S. L. and maintained at Centro de
Investigacio ´n en Sanidad Animal (CISA-INIA) for one to two
weeks to allow their acclimatization. Mice were inoculated
subcutaneously in the left rear footpad (FP) with 50 ml of FMDV
or culture medium (negative controls). The specific number of
PFU inoculated and the experimental conditions are indicated in
the corresponding footnote or Results section. Animals were
examined daily for clinical symptoms. All the experiments with live
animals were performed under the guidelines of the European
Community (86/609/EEC) and were approved by the site ethical
review committee.
RNA extraction, cDNA synthesis, PCR amplification, and
nucleotide sequencing
RNA was extracted from the supernatant of cell culture
infections or from biological clones by treatment with Trizol
(Invitrogen) according to the instructions of the manufacturer.
Reverse transcription (RT) of FMDV RNA was performed using
avian myeloblastosis virus reverse transcriptase (Promega) or
Transcriptor reverse transcriptase (Roche), as specified by the
manufacturer. For the determination of the consensus sequences
(viral populations and biological clones), PCR amplification was
carried out using the Expand high-fidelity polymerase system
(Roche), as specified by the manufacturer. For the molecular
cloning of individual viral RNA molecules from FMDV C-S8c1
and viral population P9 R, PCR amplification was carried out
using PfuUltra DNA polymerase (Stratagene), due to its high
copying fidelity [58,59], as previously documented [60]. Nucleo-
tide sequencing was carried as described in [57,61].
Molecular cloning
The genetic complexity of FMDV C-S8c1 and P9 R
populations was analyzed by molecular cloning of the genomic
region spanning residues 6800 to 7773, which corresponds to most
of the viral polymerase gene (3D) (3D amino acids 65 to 453). PCR
amplification was performed as indicated above with primers
spanning FMDV residues 6610–6631 (forward orientation) and
7992–7953 (reverse orientation). cDNA products were purified
and digested with the restriction enzymes HindIII (position 6667)
and XhoI (position 7831) (New England BioLabs), and ligated to
plasmid pGEM-4Z (Promega), previously digested with the same
restriction enzymes, and treated with shrimp alkaline phosphatase
(New England BioLabs). Transformation of E. coli DH5a, colony
screening by PCR amplification, and nucleotide sequencing of
individual clones were carried out as previously described [16].
Twenty-seven and 30 independent clones from populations P9 R
and C-S8c1, respectively, were sequenced (a total of 26,000 to
29,000 nucleotides per viral population). DNA from positive
colonies was amplified with the Expand high-fidelity polymerase
system (Roche) according to the manufacturer’s protocol, and
sequenced as described above.
Figure 6. Suppressive effect of the mutagenized population P9 R on FMDV C-S8c1. Two groups of mice were inoculated subcutaneously
with either 50 PFU of C-S8c1 (six mice) or a mixed population comprising 50 PFU of C-S8c1 and 10
3 PFU of P9 R (10 mice). The nomenclature of the
virus is as described in Figure 1. Mice were monitored during a follow-up period of 168 hours and the percentage of survival in each group is
represented.
doi:10.1371/journal.pone.0039941.g006
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FMDV RNA quantification was performed by real-time RT-
PCR using the LightCycler instrument (Roche) and the RNA
master SYBR green I kit (Roche), as specified by the manufac-
turer. Primers spanning FMDV genomic residues 4924 to 4944
(forward) and 5026 to 5047 (reverse) were used in the amplification
[numbering of the FMDV genome residues is according to [61].
Quantification was relative to a standard curve obtained with
known amounts of in vitro transcribed FMDV RNA, and was
carried out as previously described [16,55].
Characterization of mutant spectra
The complexity of mutant spectra was characterized by
determination of the mutation frequency and the normalized
Shannon entropy, calculated with the formula Sn= 2[gi (pi x
lnpi)]/ln N, in which pi is the proportion of each sequence of the
mutant spectrum and N is the total number of sequences
compared [62], as previously described [16,41,56,63].
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